Fig. 2From: Efficacy and safety of temozolomide-based regimens in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysisForest plots of individual and pooled effect sizes of a ORR, b DCR, and c having more than 50% decrease in chromogranin A levelsBack to article page